• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Big Rock Partners Acquisition Corp. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    4/21/21 5:15:37 PM ET
    $BRPA
    Business Services
    Finance
    Get the next $BRPA alert in real time by email
    8-K 1 brpa_8k.htm CURRENT REPORT brpa_8k
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    ______________
     
    FORM 8-K
     
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934
     
    Date of Report (Date of earliest event reported): April 21, 2021
     
    BIG ROCK PARTNERS ACQUISITION CORP.
    (Exact Name of Registrant as Specified in Charter)
     
    Delaware
     
    001-38302
     
    82-2844431
    (State or Other Jurisdiction
    of Incorporation)
     
    (Commission
    File Number)
     
    (IRS Employer
    Identification No.)
     
    2645 N. Federal Highway, Suite 230
    Delray Beach, FL
     
     
    33483
    (Address of Principal Executive Offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code:  202-654-7060
     
    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐ 
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐ 
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐ 
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐ 
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     Trading Symbol(s)
    Name of each exchange on which registered
    Units, each consisting of one share of Common Stock, one Right and one-half of one Warrant
     BRPAU
    The NASDAQ Stock Market LLC
    Common Stock, par value $0.001 per share
     BRPA
    The NASDAQ Stock Market LLC
    Rights, exchangeable into one-tenth of one share of Common Stock
     BRPAR
    The NASDAQ Stock Market LLC
    Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50
     BRPAW
    The NASDAQ Stock Market LLC
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☒
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □
     

     
     
     
    Item 5.03  Amendments to Articles of Incorporation or Bylaws
     
    The information included in Item 5.07 is incorporated by reference in this item to the extent required herein.
     
    Item 5.07. Submission of Matters to a Vote of Security Holders.
     
    On April 21, 2021, Big Rock Partners Acquisition Corp. (the “Company”) held a special meeting of its stockholders (the “Meeting”). At the Meeting, the Company’s stockholders considered the following proposal:
     
    1. A proposal to adopt and approve an amendment to the Company’s amended and restated certificate of incorporation (the “Charter”) to extend the date that the Company has to consummate a business combination (the “Extension”) to May 24, 2021 (the “Extended Date”). The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders:
     
    For
    Against
    Abstain
    Broker Non-Votes
    1,729,484
    1,434
    0
    0
     
    Stockholders holding an aggregate of 330 public shares exercised their right to convert such shares of the Company’s common stock into cash in connection with the Extension.
     
    Following the Meeting, the Company filed the amendment to the Charter with the Secretary of State of the State of Delaware. A copy of the amendment is attached hereto as Exhibit 3.1. The Company now has until May 24, 2021 to consummate an initial business combination.
     
    Item 9.01. Financial Statement and Exhibits.
     
    (d)            
    Exhibits:
     
    Exhibit
     
    Description
     
     
     
    3.1
     
    Amendment to Amended and Restated Certificate of Incorporation
     
     
     
     
     
    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    BIG ROCK PARTNERS ACQUISITION CORP.
     
     
     
     
     
    Dated: April 21, 2021
    By:  
    /s/ Richard Ackerman
     
     
    Name;  
    Richard Ackerman 
     
     
    Title:  
    Chairman, President and Chief Executive Officer 
     
     
     
     
     
     
     
    Get the next $BRPA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRPA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BRPA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

    RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ:NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a conference call Tuesday, August 17, 2021, at 8:30AM Eastern Time to discuss its business update and second quarter financial results. "NRx is pleased to report its first quarterly results as a publicly-traded company. We have continued to make substantial progress as a company with the filing of an EUA request for ZYESAMI in the US on May 31st, and the filing and granting of an EUA in the Nation of Georgia, with first orders expected shortly. We are honored to

    8/16/21 9:32:00 PM ET
    $BRPA
    $NRXP
    Business Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA)

    RADNOR, Pa., May 25, 2021 /PRNewswire/ -- Today, NeuroRx, Inc., announced it has been approved by the Nasdaq for listing on the Nasdaq Global Market, following the completion of its business combination with Big Rock Partners Acquisition Corp. (NASDAQ:BRPA). The combined entity is NRx Pharmaceuticals, Inc. and will trade on the Nasdaq Global Market as NRXP. NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP"Today marks a major milestone as we include public investors in our quest to bring innovative medicines to patients at immediate risk of death, who have no curr

    5/25/21 6:48:00 AM ET
    $BRPA
    Business Services
    Finance

    Big Rock Partners Acquisition Corp. Announces Effectiveness of Registration Statement; Confirms Annual Meeting Date of May 24, 2021 to Approve Proposed Merger with NeuroRx

    Big Rock Partners Recommends All Stockholders Vote "FOR" ALL Proposals at Annual Meeting NEW YORK, NY / ACCESSWIRE / May 21, 2021 / Big Rock Partners Acquisition Corp. ("Big Rock" or "BRPA") (NASDAQ:BRPA), a publicly traded special purpose acquisition company, today confirmed that its Annual Meeting of Stockholders (the "Annual Meeting") to consider the previously announced merger agreement with NeuroRx, Inc. ("NeuroRx" or the "Company") will take place on May 24, 2021. Stockholders of record as of April 23, 2021 (the "Record Date") are eligible to vote at the Annual Meeting.Big Rock also announced that the U.S. Securities and Exchange Commission has declared effective its registration state

    5/21/21 6:40:00 PM ET
    $BRPA
    Business Services
    Finance

    $BRPA
    SEC Filings

    View All

    SEC Form 8-K filed by Big Rock Partners Acquisition Corp.

    8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    5/28/21 5:26:36 PM ET
    $BRPA
    Business Services
    Finance

    Big Rock Partners Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Change in Shell Company Status

    8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    5/28/21 5:26:03 PM ET
    $BRPA
    Business Services
    Finance

    SEC Form 8-K filed by Big Rock Partners Acquisition Corp.

    8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    5/26/21 4:13:58 PM ET
    $BRPA
    Business Services
    Finance

    $BRPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: BRAC Lending Group LLC returned 869,565 units of Common Stock to the company, decreasing direct ownership by 60% to 590,435 units (Amendment)

    4/A - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    6/4/21 9:40:44 AM ET
    $BRPA
    Business Services
    Finance

    SEC Form 4 filed by Big Rock Partners Acquisition Corp.

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    5/25/21 9:17:34 PM ET
    $BRPA
    Business Services
    Finance

    SEC Form 4 filed by Big Rock Partners Acquisition Corp.

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    5/25/21 8:02:21 PM ET
    $BRPA
    Business Services
    Finance

    $BRPA
    Financials

    Live finance-specific insights

    View All

    NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

    RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ:NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a conference call Tuesday, August 17, 2021, at 8:30AM Eastern Time to discuss its business update and second quarter financial results. "NRx is pleased to report its first quarterly results as a publicly-traded company. We have continued to make substantial progress as a company with the filing of an EUA request for ZYESAMI in the US on May 31st, and the filing and granting of an EUA in the Nation of Georgia, with first orders expected shortly. We are honored to

    8/16/21 9:32:00 PM ET
    $BRPA
    $NRXP
    Business Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Big Rock Partners Acquisition Corp. (Amendment)

    SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    6/4/21 10:17:16 AM ET
    $BRPA
    Business Services
    Finance

    SEC Form SC 13D filed by Big Rock Partners Acquisition Corp.

    SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    6/3/21 5:30:14 PM ET
    $BRPA
    Business Services
    Finance

    SEC Form SC 13D/A filed by Big Rock Partners Acquisition Corp. (Amendment)

    SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    5/26/21 5:02:30 PM ET
    $BRPA
    Business Services
    Finance